In the last trading session, 1.62 million Cytokinetics Inc (NASDAQ:CYTK) shares changed hands as the company’s beta touched 0.57. With the company’s per share price at $30.75 changed hands at -$0.25 or -0.81% during last session, the market valuation stood at $3.67B. CYTK’s last price was a discount, traded about -99.67% off its 52-week high of $61.40. The share price had its 52-week low at $29.31, which suggests the last value was 4.68% up since then.
Analysts gave the Cytokinetics Inc (CYTK) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.36. If we narrow down to specifics, the data shows that 0 out of 12 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended CYTK as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight.
Cytokinetics Inc (NASDAQ:CYTK) trade information
Instantly CYTK was in red as seen at the end of in last trading. With action -4.30%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -34.63%, with the 5-day performance at -4.30% in the red. However, in the 30-day time frame, Cytokinetics Inc (NASDAQ:CYTK) is -22.11% down.
The consensus price target for the stock as assigned by Wall Street analysts is 61, meaning bulls need an upside of 49.59% from its current market value. According to analyst projections, CYTK’s forecast low is 55 with 67 as the target high. To hit the forecast high, the stock’s price needs a -117.89% plunge from its current level, while the stock would need to soar -78.86% for it to hit the projected low.
Cytokinetics Inc (CYTK) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -20.02%. The 2025 estimates are for Cytokinetics Inc earnings to decrease by -8.77%, but the outlook for the next 5-year period is at 15.83% per year.
Cytokinetics Inc (NASDAQ:CYTK)’s Major holders
FMR LLC holds the second largest percentage of outstanding shares, with 10.5485% or 11.52 million shares worth $624.32 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and iShares Trust-iShares Core S&P Mid-Cap ETF. With 4.07 shares estimated at $125.09 million under it, the former controlled 3.41% of total outstanding shares. On the other hand, iShares Trust-iShares Core S&P Mid-Cap ETF held about 3.23% of the shares, roughly 3.85 shares worth around $118.54 million.
